Details

Autor(en) / Beteiligte

• Löwik, Marije M
• Lam, Ming Kai
• Sen, Hanim
• Tandjung, Kenneth
• van Houwelingen, K Gert
• de Man, Frits H A F
• Stoel, Martin G
• Louwerenburg, J Hans W
• Linssen, Gerard C M
• Doggen, Carine J M
• von Birgelen, Clemens

Titel

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

Ist Teil von

• EuroIntervention, 2015-03, Vol.10 (11), p.1276-1279

Ort / Verlag

France

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• To assess three-year clinical outcome following randomised use of the second-generation Resolute zotarolimus-eluting stent (ZES) and the XIENCE V everolimus-eluting stent (EES). For Resolute ZES and randomised use, outcome data ≥3 years are relatively scarce. The TWENTE trial examined 1,391 patients with stable angina or non-ST-elevation acute coronary syndromes, of whom 21.6% were diabetics, 70.1% had complex B2 or C lesions and 77.4% had "off-label" indications for DES use. Three-year follow-up data were obtained in 1,381 patients (99.3%; 10 withdrawals). Adverse clinical events were independently adjudicated. The primary endpoint target vessel failure (TVF), a composite of cardiac death, target vessel-related myocardial infarction and clinically indicated target vessel revascularisation, was 12.1% for Resolute ZES and 13.4% for XIENCE V EES (p=0.50). Cardiac death rates were 1.9% vs. 3.5% (p=0.06); the other individual components of TVF also showed no significant between-group differences. The rates of definite-or-probable stent thrombosis (1.4% vs. 1.6%, p=0.82) and very late stent thrombosis (0.6% vs. 0.4%, p=1.0) did not differ between the groups. Three-year follow-up data of patients included in the randomised TWENTE trial demonstrated similar and sustained safety and efficacy of Resolute ZES and XIENCE V EES.